Featured Research

from universities, journals, and other organizations

Uncapping the mystery behind the mechanism of cap removal from actin filaments

Date:
July 6, 2010
Source:
Public Library of Science
Summary:
In a new study, researchers present the X-ray crystal structures of the actin capping protein complexed with its inhibitors, V-1 and CARMIL, and demonstrate that the two regulators modulate the filament capping activity in very different manners.

In a new study, Shuichi Takeda at Nagoya University and colleagues present the X-ray crystal structures of the actin capping protein (CP) complexed with its inhibitors, V-1 and CARMIL, and demonstrate that the two regulators modulate the filament capping activity in very different manners.

These findings will be published in the online, open access journal PLoS Biology.

Dynamic rearrangement of actin cytoskeleton structure is fundamental to many cellular processes, such as neuronal development, immune response, and cancer metastasis. CP is a key regulator of actin, capping tightly to the dynamic end of the filament (the barbed end) to limit elongation. V-1 completely inhibits free CP from interacting with actin, whereas CARMIL acts on the barbed end-bound CP and uncaps the filament. However, the molecular mechanisms by which the two inhibitors modulate the capping activity remain poorly understood.

The new structures clearly indicate that while V-1 directly blocks the actin-binding site of CP preventing filament capping, CARMIL does not. So how does CARMIL uncap the filament? A clue was provided by a structural comparison analysis: CP has two stable domains that are continuously twisting relative to each other. Since CARMIL binds CP across the two domains like a chain, the authors concluded that CARMIL inhibits CP by suppressing the twisting movement required for tight-barbed end capping.

According to the authors, "CP is not a constitutively active inhibitor of barbed-end elongation; rather, the capping activity of CP is fine-tuned for the highly orchestrated assembly of the cellular actin machinery, and the conformational flexibility of CP provides the structural basis for the regulation." The new findings will pave the way for understanding the regulating mechanisms of actin dynamics that drives cell movement.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Takeda S, Minakata S, Koike R, Kawahata I, Narita A, et al. Two Distinct Mechanisms for Actin Capping Protein Regulation-Steric and Allosteric Inhibition. PLoS Biol, 2010; 8 (7): e1000416 DOI: 10.1371/journal.pbio.1000416

Cite This Page:

Public Library of Science. "Uncapping the mystery behind the mechanism of cap removal from actin filaments." ScienceDaily. ScienceDaily, 6 July 2010. <www.sciencedaily.com/releases/2010/07/100706171119.htm>.
Public Library of Science. (2010, July 6). Uncapping the mystery behind the mechanism of cap removal from actin filaments. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/07/100706171119.htm
Public Library of Science. "Uncapping the mystery behind the mechanism of cap removal from actin filaments." ScienceDaily. www.sciencedaily.com/releases/2010/07/100706171119.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins